Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SymBio Pharmaceuticals Limited (4582.T)
Tokyo, JP
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.22% | -3.30% | -10.20% | +1.15% | -20.72% | -2.22% | -42.86% | -75.89% | -92.80% | -93.39% | -94.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-46.7% Q1'26: -11.6% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-11.9% Q1'26: -28.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-379.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-351.7% Q1'26: -1,002.8% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%-1,239.5% Q1'26: +1,466.1% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+11.3% Q1'26: +41.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.43× Q1'26: -0.11× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.93B
est: 1.96B (-1.4%)
|
2.37B
est: 2.03B (+16.9%)
|
3.44B
est: 3.60B (-4.2%)
|
3.84B
est: 4.21B (-8.8%)
|
2.84B
est: 3.05B (-7.1%)
|
2.99B
est: 3.04B (-1.7%)
|
8.25B
est: 9.08B (-9.1%)
|
10.01B
est: 10.00B (+0.1%)
|
5.59B
est: 7.00B (-20.1%)
|
2.45B
est: 12.80B (-80.8%)
|
1.31B
est: 1.31B (+0.0%)
|
| EBITDA |
-2.60B
est: -700.72M (-271.6%)
|
-2.28B
est: -724.01M (-215.4%)
|
-3.92B
est: -1.29B (-204.7%)
|
-2.62B
est: -1.50B (-74.3%)
|
-4.26B
est: -1.09B (-290.5%)
|
-4.44B
est: -1.09B (-308.8%)
|
1.11B
est: -3.24B (+134.2%)
|
2.06B
est: -3.58B (+157.7%)
|
-714.00M
est: -2.50B (+71.5%)
|
-3.78B
est: -4.58B (+17.4%)
|
-4.60B
est: -467.42M (-884.0%)
|
| EBIT |
-2.63B
est: -715.76M (-267.2%)
|
-2.31B
est: -739.55M (-212.3%)
|
-3.95B
est: -1.31B (-200.6%)
|
-2.66B
est: -1.54B (-72.9%)
|
-4.30B
est: -1.12B (-285.7%)
|
-4.51B
est: -1.11B (-306.0%)
|
1.02B
est: -3.31B (+130.7%)
|
1.96B
est: -3.65B (+153.8%)
|
-811.67M
est: -2.56B (+68.2%)
|
-3.88B
est: -4.67B (+17.0%)
|
-4.60B
est: -477.45M (-863.3%)
|
| Net Income |
-2.63B
est: -14.47B (+81.8%)
|
-2.31B
est: -13.88B (+83.3%)
|
-3.98B
est: -14.84B (+73.2%)
|
-2.75B
est: -8.29B (+66.8%)
|
-4.38B
est: -7.71B (+43.3%)
|
-4.09B
est: -5.56B (+26.5%)
|
2.03B
est: 1.33B (+53.3%)
|
1.18B
est: 1.91B (-38.3%)
|
-1.96B
est: -428.42M (-358.1%)
|
-3.83B
est: 2.22B (-272.3%)
|
-4.78B
|
| SGA |
3.13B
est: 1.22B (+155.9%)
|
3.03B
est: 1.27B (+139.5%)
|
4.98B
est: 2.25B (+121.5%)
|
3.83B
est: 2.63B (+45.6%)
|
5.17B
est: 1.91B (+170.7%)
|
3.07B
est: 1.90B (+61.4%)
|
2.98B
est: 5.67B (-47.5%)
|
3.08B
est: 6.25B (-50.7%)
|
2.58B
est: 4.37B (-40.9%)
|
2.37B
est: 9.46B (-74.9%)
|
2.09B
est: 966.73M (+116.3%)
|
| EPS |
-325.04
est: -320.86 (-1.3%)
|
-235.27
est: -307.82 (+23.6%)
|
-319.14
est: -329.03 (+3.0%)
|
-165.54
est: -183.80 (+9.9%)
|
-189.03
est: -171.00 (-10.5%)
|
-124.13
est: -123.40 (-0.6%)
|
53.04
est: 29.40 (+80.4%)
|
30.20
est: 42.40 (-28.8%)
|
-49.19
est: -9.50 (-417.8%)
|
-85.00
est: 44.30 (-291.9%)
|
-95.12
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Edwin Rock | Corporate Officer, Corporate VP and Head of Global R&D Division | — | — |
| Fuminori Yoshida | Chief Executive Officer, President & Representative Director | — | male |
| Hiroyuki Horita | Corporate Officer | — | — |
| Masahiko Okuno | Corporate Officer | — | — |
| Minori Rosales | Corporate Officer, CMO of Oncology & Head of Japan Development Division | — | — |
| Takeo Okuno | Corporate Officer & CFO | — | — |
| Yoshiharu Torikai | Corporate Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4582.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
